Trial Profile
Clinical Trials Insight: 700043596
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2009
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary) ; Dronabinol (Primary)
- Indications Chemotherapy-induced nausea and vomiting; Neuropathic pain
- Focus Pharmacokinetics
- Sponsors Cynapsus Therapeutics; IntelGenx Corp.
- 20 Apr 2009 New trial record.
- 14 Apr 2009 Results reported in a Cannasat Therapeutics media release.